Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.

Alessandro Russo,Katherine A Scilla,Ranee Mehra,Allison Gittens,Michael G McCusker,Diego de Miguel-Perez,Jorge E Gomez,Ariel Peleg,Marzia Del Re,Christian D Rolfo

Clinical lung cancer（2023）

引用 0|浏览22

暂无评分

摘要

•Plasma NGS can track the clonal evolution of EGFR-mutated NSCLCs.•C797S mutation is one of the most common mechanisms of acquired resistance to osimertinib.•First generation can target C797S mutants, albeit responses are usually transient.•Novel therapeutic strategies are eagerly awaited for overcoming C797S mutation.

查看译文

关键词

Acquired resistance,Osimertinib,Plasma NGS,Liquid biopsy,Rechallenge

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要